Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andexanet Posology and Interaction With Enoxaparin in Healthy Participants
NCT07312851Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2026
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of andexanet alfa (14 arms), sponsored by AstraZeneca. Primary endpoints: Anti-Factor Xa activity at Day 1, Change from baseline in anti-Factor Xa activity at Day 1 and 8 more. Started Jan 2026; status: completed.
02
Drugs
andexanet alfa
Beyond the preview
Go deeper on NCT07312851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07312851.